No Data
No Data
Morgan Stanley Initiates TScan Therapeutics(TCRX.US) With Buy Rating, Announces Target Price $10
Express News | TScan Therapeutics Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $10
TD Cowen Maintains TScan Therapeutics(TCRX.US) With Buy Rating
Barclays Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Cuts Target Price to $3
Barclays Maintains Overweight on TScan Therapeutics, Lowers Price Target to $3
TScan Therapeutics Price Target Lowered to $3 From $14 at Barclays